Ozempic

October 15, 2024 7:25 PM

Britain to study use of weight loss drug to get people back to work

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high rate of long-term sickness that has become a major drag on the economy. Health minister Wes Streeting predicted the use of the drug - a competitor to Novo Nordisk's Ozempic - could help transform the health of the nation, after Lilly announced a 279 million pound ($365 million) investment in Britain as part of a flagship summit hosted by Prime Minister Keir Starmer. The dea...

September 11, 2024 4:36 PM

Novo Nordisk experimental obesity pill has mild-to-moderate side effects in early trial

Novo Nordisk said on Wednesday that its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects. The maker of blockbuster drugs Wegovy and Ozempic said in March that a Phase I trial of the pill version of amycretin showed participants lost up to 13.1% of their weight after 12 weeks, prompting shares to surge more than 8%. That compared to weight loss of about 6% after 12 weeks and 15% after 68 we...

July 30, 2024 3:52 PM

Ozempic linked to less tobacco-related healthcare use in study

Smokers with type 2 diabetes taking Novo Nordisk’s Ozempic had fewer tobacco-related medical encounters and fewer interventions to help them quit smoking than those who received other diabetes drugs, according to a study of electronic health records published on Monday. In the year after starting treatment, Ozempic users with a previous diagnosis of tobacco use disorder were up to 32% less likely to discuss tobacco use with a healthcare provider than those taking other diabetes medications. T...

July 9, 2024 4:57 PM

Novo Nordisk shares down after analysis finds Lilly drug leads to better weight loss

Shares in Novo Nordisk, maker of the wildly popular obesity drug Wegovy were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly's own treatment Mounjaro leads to faster and greater weight loss. The analysis was published on Monday in JAMA Internal Medicine, a medical journal. It examined health records and other data to assess the pace and percentage of weight loss for overweight and obese people taking tirzepatide - the active ingredient in Lilly's Mounjaro a...